Proteolix, Inc. presented results from the company"s most advanced clinical trial of single-agent carfilzomib demonstrating anti-cancer activity and progression-free survival in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.